Literature DB >> 17627901

Risk for active tuberculosis in inflammatory bowel disease patients.

Faten N Aberra1, Nicolas Stettler, Colleen Brensinger, Gary R Lichtenstein, James D Lewis.   

Abstract

BACKGROUND & AIMS: The primary aim of this study was to determine the incidence of active tuberculosis in an inflammatory bowel disease population compared with the general population before the availability of infliximab.
METHODS: We performed a retrospective cohort study with the General Practice Research Database from January 1988-October 1997. Ulcerative colitis and Crohn's disease subjects with a minimum of 1 year of follow-up were matched to randomly selected subjects from the remaining population on year of birth (+/-5 years), sex, and primary care practice at ratio of 1:4. Active tuberculosis was determined by tuberculosis diagnostic codes. The incidence of active tuberculosis in the inflammatory bowel disease population and the relative risk for active tuberculosis in inflammatory bowel disease population compared with the general population were calculated. Multivariate logistic regression analysis was performed to adjust for confounders.
RESULTS: There were 16,213 inflammatory bowel disease subjects and 66,512 control subjects. The annual incidence of active tuberculosis was 20/100,000 in inflammatory bowel disease subjects compared with 9/100,000 in control subjects, yielding an unadjusted relative risk for active tuberculosis of 2.36 (95% confidence interval, 1.17-4.74). Adjusting for confounders, corticosteroid use and smoking, the odds ratio of inflammatory bowel disease for active tuberculosis was 1.88 (95% confidence interval, 0.68-5.20).
CONCLUSIONS: During the pre-infliximab era, inflammatory bowel disease subjects appeared to be at higher risk for active tuberculosis than the general population, with immunosuppressant medications likely the main reason for this increased risk.

Entities:  

Mesh:

Year:  2007        PMID: 17627901     DOI: 10.1016/j.cgh.2007.04.007

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  14 in total

Review 1.  Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.

Authors:  D C Sadowski; C N Bernstein; A Bitton; K Croitoru; R N Fedorak; A Griffiths
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

Review 2.  Vaccines and recommendations for their use in inflammatory bowel disease.

Authors:  María Dolores Sánchez-Tembleque; Carmen Corella; Jose L Pérez-Calle
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

Review 3.  What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?

Authors:  Ian C Lawrance
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

4.  A Study of Optimal Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Disease.

Authors:  Talal Al-Taweel; Matthew Strohl; Madhukar Pai; Myriam Martel; Talat Bessissow; Alain Bitton; Ernest Seidman; Waqqas Afif
Journal:  Dig Dis Sci       Date:  2018-07-03       Impact factor: 3.199

5.  Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn's Disease.

Authors:  Haruhiko Ogata; Mamoru Watanabe; Toshiyuki Matsui; Hidenori Hase; Motohiro Okayasu; Tsuyoshi Tsuchiya; Yasuhiko Shinmura; Toshifumi Hibi
Journal:  J Crohns Colitis       Date:  2016-03-09       Impact factor: 9.071

6.  Features of indeterminate results of QuantiFERON-TB Gold In-Tube test in patients with haematological malignancies.

Authors:  Chen-Cheng Huang; Chieh-Lin Jerry Teng; Ming-Feng Wu; Ching-Hsiao Lee; Hui-Chen Chen; Wei-Chang Huang
Journal:  Ther Adv Hematol       Date:  2021-07-06

7.  Associations between selected immune-mediated diseases and tuberculosis: record-linkage studies.

Authors:  Sreeram V Ramagopalan; Raph Goldacre; Andrew Skingsley; Chris Conlon; Michael J Goldacre
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

8.  The increased risk of active tuberculosis disease in patients with dermatomyositis - a nationwide retrospective cohort study.

Authors:  Ping-Hsun Wu; Yi-Ting Lin; Yi-Hsin Yang; Yu-Chih Lin; Yi-Ching Lin
Journal:  Sci Rep       Date:  2015-11-17       Impact factor: 4.379

9.  Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern Italy.

Authors:  Marco Ardesia; Giuseppe Costantino; Placido Mondello; Angela Alibrandi; Walter Fries
Journal:  Gastroenterol Res Pract       Date:  2017-09-17       Impact factor: 2.260

Review 10.  Systematic review and meta-analysis on the association of tuberculosis in Crohn's disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα).

Authors:  Brent L Cao; Ahmad Qasem; Robert C Sharp; Latifa S Abdelli; Saleh A Naser
Journal:  World J Gastroenterol       Date:  2018-07-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.